Fig. 1

Agents in clinical development in MF. i—inhibitor; JAK—Janus-associated Kinase; PIM—Proviral Integration Site for Moloney Murine Leukemia Virus; PI3K—Phosphatidylinositol 3-Kinase; TGF—tumor growth factor; Hsp—heat-shock protein; AURKA—Aurora Kinase A;GSK—glycogen synthase kinase; NCT—nuclear-cytoplasmic transport; MAB—monoclonal antibody; NEDD—neddylation; BH—B-cell lymphoma homology; MDM—murine double minute; SMAC—second mitochondria-derived activator of caspases; TRAIL—tumor necrosis factor-related apoptosis inducing ligand; DNMT—DNA methyl transferase; IDH—isocitrate dehydrogenase; BET—bromodomain and extra-terminal motif; LSD1—lysine-specific demethylase 1